Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Am J Emerg Med. 2021 Jun 29;49:343–351. doi: 10.1016/j.ajem.2021.06.049

Table 4.

Secondary outcomes.

Received capsaicin (n = 149) Did not receive capsaicin (n = 52) p OR 95% CI β
Secondary outcomes

Total ED length of stay (median) – hours 6.1 5.25 0.372
Total medications for symptom relief received – median, No. (range) 4 (0–60) 4 (0–43) 0.934
Admitted due to uncontrolled CHS symptoms – No. (%) 39 (26.2) 13 (25) 0.868 1.01 0.8190–1.183
Return to ED in 24 h for same symptoms or complaint – No. (%) 8 (5.4) 3 (5.8) 0.913 1.02 0.704–1.479
Time to discharge or admission after administration of capsaicin or first agent (average) – hours 3.72 6.11 0.001 2.799–3.501
Change in pain score after administration of capsaicin or first agent – average (126 complete records) +0.94 +1.38 0.464 −1.636 - 0.750 −0.443
Change in episodes of emesis after administration of capsaicin or first agent (14 complete records) +0.03 −0.21 0.423 −3.575–1.624 −0.975